{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:35:24Z","timestamp":1777624524728,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.jaad.2011.08.025","type":"journal-article","created":{"date-parts":[[2011,10,2]],"date-time":"2011-10-02T02:01:15Z","timestamp":1317520875000},"page":"673-679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Leflunomide in dermatology"],"prefix":"10.1016","volume":"66","author":[{"given":"Alan S.","family":"Boyd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2011.08.025_bib1","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra032906","article-title":"New drugs for rheumatoid arthritis","volume":"350","author":"Olsen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2011.08.025_bib2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.59.11.841","article-title":"Leflunomide: mode of action in the treatment of rheumatoid arthritis","volume":"59","author":"Breedveld","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2011.08.025_bib3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00124743-200112000-00003","article-title":"Open trial of leflunomide for refractory psoriasis and psoriatic arthritis","volume":"7","author":"Liang","year":"2001","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib4","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2011.08.025_bib5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000091251","article-title":"Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study","volume":"212","author":"Nash","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2011.08.025_bib6","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/ard.2007.072652","article-title":"A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis","volume":"67","author":"Ravindran","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2011.08.025_bib7","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2230.2002.01150.x","article-title":"Mycophenolate mofetil and leflunomide: promising compounds for the treatment of skin diseases","volume":"27","author":"Frieling","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib8","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/archderm.140.10.1288","article-title":"Leflunomide in psoriasis and psoriatic arthritis: a preliminary study","volume":"140","author":"Thami","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib9","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/rheumatology\/keg156","article-title":"Successful treatment of sarcoidosis with leflunomide","volume":"42","author":"Majithia","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2011.08.025_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jaad.2007.08.014","article-title":"Leflunomide as adjuvant treatment of dermatomyositis","volume":"58","author":"Boswell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0049-0172(99)80034-1","article-title":"Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis","volume":"29","author":"Kremer","year":"1999","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2011.08.025_bib12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0006-2952(96)00303-6","article-title":"Two activities of the immunosuppressive metabolite of leflunomide, A77 1726: inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation","volume":"52","author":"Xu","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jaad.2011.08.025_bib13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1046\/j.1365-2133.2002.4653_5.x","article-title":"Treatment of severe psoriasis and psoriatic arthritis with leflunomide","volume":"146","author":"Reich","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib14","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-2133.2009.09227.x","article-title":"Successful treatment of multicentric reticulohistiocytosis with leflunomide","volume":"161","author":"Lonsdale-Eccles","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib15","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0006-2952(97)00677-1","article-title":"Differential modulation of pro- and anti-inflammatory cytokine receptors by N-(trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator leflunomide","volume":"55","author":"Mirmohammadsadcgh","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jaad.2011.08.025_bib16","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1365-2133.2004.05836.x","article-title":"Leflunomide in the treatment of psoriasis: results of a phase II open trial","volume":"150","author":"Tacuilo-Parra","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib17","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/j.0007-0963.2003.05846.x","article-title":"Leflunomide as a novel treatment option in severe atopic dermatitis","volume":"150","author":"Schmitt","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib18","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B","article-title":"Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate","volume":"44","author":"Cohen","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2011.08.025_bib19","first-page":"1182","article-title":"Leflunomide for the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"30","author":"Osiri","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib20","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/1529-0131(200105)44:5<1048::AID-ANR184>3.0.CO;2-V","article-title":"Leflunomide-associated weight loss in rheumatoid arthritis","volume":"44","author":"Coblyn","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2011.08.025_bib21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2165\/00002018-200427050-00006","article-title":"Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity","volume":"27","author":"van Roon","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2011.08.025_bib22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1563-2571.2000.00034.x","article-title":"Severe pancytopenia after leflunomide in rheumatoid arthritis","volume":"27","author":"Auer","year":"2000","journal-title":"Acta Med Austriaca"},{"key":"10.1016\/j.jaad.2011.08.025_bib23","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1136\/ard.2005.038265","article-title":"Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide","volume":"64","author":"Metzler","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2011.08.025_bib24","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.21806","article-title":"Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis","volume":"54","author":"Suissa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2011.08.025_bib25","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/rheumatology\/kep052","article-title":"Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis","volume":"48","author":"Sawada","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2011.08.025_bib26","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3109\/s10165-008-0088-2","article-title":"Proposals for leflunomide use to avoid lung injury inpatients with rheumatoid arthritis","volume":"18","author":"Inokuma","year":"2008","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib27","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2165\/11316650-000000000-00000","article-title":"Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing","volume":"32","author":"Alcorn","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2011.08.025_bib28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","article-title":"Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicenter trial","volume":"353","author":"Smolen","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2011.08.025_bib29","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/bmj.325.7376.1333","article-title":"Leflunomide can potentiate the anticoagulant effect of warfarin","volume":"325","author":"Lim","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2011.08.025_bib30","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2165\/00003495-199958060-00010","article-title":"Leflunomide: a review of its use in active rheumatoid arthritis","volume":"58","author":"Prakash","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2011.08.025_bib31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2230.2004.01527.x","article-title":"Subacute cutaneous lupus erythematosus associated with leflunomide","volume":"29","author":"Kerr","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib32","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1365-2230.2005.01898.x","article-title":"Subacute cutaneous lupus erythematosus precipitated by leflunomide","volume":"30","author":"Chan","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib33","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/rheumatology\/keh586","article-title":"Leflunomide-induced subacute cutaneous lupus erythematosus","volume":"44","author":"Goeb","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2011.08.025_bib34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ard.2003.019323","article-title":"Lupus erythematosus with leflunomide: induction or reactivation?","volume":"64","author":"Gensburger","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2011.08.025_bib35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/0961203307087189","article-title":"Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions","volume":"17","author":"Marzano","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2011.08.025_bib36","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000074120","article-title":"Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide","volume":"207","author":"Fischer","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2011.08.025_bib37","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/j.1365-4632.2006.03003.x","article-title":"Leflunomide-induced toxic epidermal necrolysis","volume":"45","author":"Teraki","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib38","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jbspin.2007.08.013","article-title":"Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis","volume":"75","author":"Hassikou","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jaad.2011.08.025_bib39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/15569520701662866","article-title":"Severe cutaneous adverse drug reaction to leflunomide: a report of two cases","volume":"27","author":"Jian","year":"2008","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.jaad.2011.08.025_bib40","first-page":"1102","article-title":"Lichen planus-like eruption: case report","volume":"113","author":"Statescu","year":"2009","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"10.1016\/j.jaad.2011.08.025_bib41","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000077307","article-title":"Photodistributed lichenoid drug eruption with rhabdomyolysis occurring during leflunomide therapy","volume":"208","author":"Rivarola de Gutierrez","year":"2004","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2011.08.025_bib42","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2133.2006.07586.x","article-title":"Reiter syndrome triggered by adalimumab (Humira\u00ae) and leflunomide (Arava\u00ae) in a patient with ankylosing spondylarthropathy and Crohn\u2019s disease","volume":"156","author":"Thielen","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib43","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000051761","article-title":"Vasculitis occurring during leflunomide therapy","volume":"203","author":"Holm","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2011.08.025_bib44","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/rheumatology\/keg120","article-title":"Leflunomide-induced vasculitis\u2013a dose response relationship","volume":"42","author":"Chan","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2011.08.025_bib45","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1345\/aph.1A347","article-title":"Leflunomide-associated skin ulceration","volume":"36","author":"McCoy","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2011.08.025_bib46","first-page":"1806","article-title":"Alopecia areata in a patient with rheumatoid arthritis treated with leflunomide","volume":"29","author":"Gottenberg","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib47","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1600-0560.2008.01162.x","article-title":"Syringotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis","volume":"36","author":"Vewel","year":"2009","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2011.08.025_bib48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.annder.2007.08.002","article-title":"Leflunomide-induced skin necrosis","volume":"135","author":"Gros","year":"2008","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2011.08.025_bib49","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1365-4632.2009.03981.x","article-title":"Cutaneous ulceration induced by leflunomide in a psoriatic patient","volume":"48","author":"Di Nuzzo","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib50","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/j.1468-3083.2007.02201.x","article-title":"Cutaneous infections with Stenotrophomonas maltophilia in patients using immunosuppressive medication","volume":"21","author":"Smeet","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2011.08.025_bib51","first-page":"S92","article-title":"Leflunomide in psoriatic polyarthritis: an Italian pilot study","volume":"44","author":"Manguso","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2011.08.025_bib52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2011.08.025_bib53","first-page":"731","article-title":"Successful treatment of SAPHO syndrome with leflunomide: report of two cases","volume":"23","author":"Scarpato","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib54","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/archdermatol.2009.256","article-title":"Leflunomide in the treatment of palmoplantar pustulosis","volume":"145","author":"Melwani","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib55","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1191\/096120301678416033","article-title":"Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study","volume":"10","author":"Remer","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2011.08.025_bib56","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1191\/0961203304lu1067sr","article-title":"Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus","volume":"13","author":"Tam","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2011.08.025_bib57","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-4632.2007.03333.x","article-title":"Leflunomide in subacute cutaneous lupus erythematosus\u2013two sides of a coin","volume":"47","author":"Suess","year":"2008","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib58","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/ard.2006.060905","article-title":"Safety and efficacy of leflunomide in primary Sj\u00f6gren\u2019s syndrome: a phase II pilot study","volume":"66","author":"van Woerkom","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2011.08.025_bib59","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/rheumatology\/kei248","article-title":"Successful treatment with leflunomide of arthritis in systemic sclerosis patients","volume":"45","author":"Sebastiani","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2011.08.025_bib60","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1136\/ard.2007.073221","article-title":"Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis","volume":"67","author":"Sangle","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2011.08.025_bib61","first-page":"6","article-title":"Severe atopic dermatitis and leflunomide: first clinical experience and highlights of pertinent experimental data","volume":"12","author":"Wozel","year":"2008","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2011.08.025_bib62","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/archderm.136.10.1204","article-title":"Bullous pemphigoid treated with leflunomide: a novel immunomodulatory agent","volume":"136","author":"Nousari","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib63","first-page":"43","article-title":"Leflunomide for chronic sarcoidosis","volume":"21","author":"Baughman","year":"2004","journal-title":"Sarcoid Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.jaad.2011.08.025_bib64","first-page":"477","article-title":"Beneficial effects of leflunomide in glucocorticoid and methotrexate-resistant Takayasu\u2019s arteritis","volume":"19","author":"Haberhauer","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2011.08.025_bib65","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1001\/archdermatol.2008.502","article-title":"Is leflunomide effective in the treatment of psoriasis in a patient who is unable to benefit from standard first- and second-line therapies and needs an affordable treatment option?","volume":"144","author":"Affleck","year":"2008","journal-title":"Arch Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221100956X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221100956X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:22:55Z","timestamp":1759270975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221100956X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S019096221100956X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2011.08.025","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leflunomide in dermatology","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2011.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}